• Loss for the period up 8.2% to $7.4 million
• Successful $5 million placement with new investors
• Progressed regulatory clearance for Salix Coronary Anatomy product with US FDA
• Commenced commercial processing of scans with first Australian client

Artrya Limited, an applied artificial intelligence healthcare company, has reported its financial results for the half-year ended 31 December 2024. The company recorded a loss of $7.4 million, up 8.2% from the prior corresponding period. This was driven by continued investment in product development, market entry, and commercialization activities. The company made significant progress on its regulatory clearance efforts, submitting an application for its Salix Coronary Anatomy product with the US Food and Drug Administration (FDA) in September 2024. Artrya received feedback from the FDA and is on track for anticipated clearance around the end of March 2025. Artrya also commenced commercial processing of scans using its Salix technology for its first client in Australia, The Cardiac Centre of NSW, providing valuable clinical validation. The company continued to advance integration efforts with other hospital systems in the US, including Tanner Health, Northeast Georgia Health System, and Cone Health.To support its ongoing commercialization efforts, Artrya successfully completed a $5 million placement to sophisticated and professional investors, including the venture arm of US hospital system Tanner Health. The funds will be applied to product development, clinical studies, regulatory work, and working capital.The company also presented two research abstracts at major industry conferences, focused on improving cardiovascular risk prediction using its technology. Overall, Artrya remains well-positioned to continue the commercialization of its patented AI platform for the detection of coronary artery disease.